000			05752cam a2200793 i 4500
001			ocn857664391
003			OCoLC
005			20171106083824.0
006			m o d
007			cr |||||||||||
008			130903s2014 nju ob 001 0 eng
010			_a 2013035811
020			_a9781118778128 (ePub)
020			_a111877812X (ePub)
020			_a9781118778159 (Adobe PDF)
020			_a1118778154 (Adobe PDF)
020			_z9780470917374 (cloth)
020			_a9781118778166
020			_a1118778162
020			_a0470917377
020			_a9780470917374
020			_a9781306571784
020			_a1306571782
029	1		_aCHVBK _b325941823
029	1		_aCHBIS _b010259524
029	1		_aNZ1 _b15922666
029	1		_aNZ1 _b16097921
029	1		_aDEBBG _bBV042792988
029	1		_aDEBBG _bBV043396198
035			_a(OCoLC)857664391 _z(OCoLC)905856541 _z(OCoLC)929527164 _z(OCoLC)960199933 _z(OCoLC)961650872 _z(OCoLC)962632779
040			_aDLC _beng _erda _cDLC _dYDX _dEBLCP _dN$T _dIDEBK _dDG1 _dYDXCP _dE7B _dCUI _dCUS _dCDX _dCOO _dRECBK _dOCLCF _dSTF _dOCLCQ _dDEBBG _dLOA
042			_apcc
049			_aMAIN
050	0	0	_aRM301.25
060	1	0	_aQV 745
072		7	_aMED _x071000 _2bisacsh
082	0	0	_a615.1/9 _223
245	0	0	_aCollaborative innovation in drug discovery : strategies for public and private partnerships / _cedited by Dr. Rathnam Chaguturu. _h[electronic resource]
264		1	_aHoboken, New Jersey : _bJohn Wiley & Sons Inc., _c[2014]
300			_a1 online resource.
336			_atext _2rdacontent
337			_acomputer _2rdamedia
338			_aonline resource _2rdacarrier
490	1		_aWiley series on technologies for the pharmaceutical industry
504			_aIncludes bibliographical references and index.
505	0		_aTable of Contents; Wiley Series on Technologies for the Pharmaceutical Industry; Title page; Copyright page; Dedication; Collaborative Drug Discovery Ethos; Foreword; Preface; About the Book; About the Editor; Contributors; Part I: Perspectives on Collaborative Innovation; 1: Productive Relationships in Research and Development between Government, Industry, and Universities; Universities, Government, and Industry: Historical Beginnings in Prussia; Refinement and Broad Adoption: the United States; General Principles for Success; Notes; 2: Divided We Fall; Challenges; Collaboration Models
505	8		_aExamples of Successful Biomedical CollaborationsPrinciples of Collaboration; Governance, Administration, and Autonomy; Human Factors; Conclusion; References; 3: Innovation: Open Source and Nonprofit Models in Drug Discovery; Why Do People Innovate?; How Do We Encourage Innovation?; Why Is Innovation Important?; Warnings Regarding Innovation in Drug Discovery; Open Source Models; Nonprofit Models; Recommendations; References; 4: The Changing Face of Innovation in Drug Discovery; Introduction; Core Objectives of the Drug Discovery Process
505	8		_aMajor Innovations in Technology Have Advanced Drug DiscoveryAn Important Trend: Academic and Pharmaceutical Organizations Are Collaborating in Support of Drug Discovery; Future Perspectives: Where Is Innovation Leading?; References; 5: Current Trends in Collaborative Drug Discovery and Strategies to De-Risk Precompetitive Initiatives; Pharmaceutical Industry's Perspective; Academia's Perspective; Open (Collaborative) Innovation: A New Business Model; Drug Discovery through Collaborations; Drug Discovery through Consortia; Drug Discovery through Repurposing Strategies
505	8		_aProbe Discovery in Public DomainEffective Management of Academia-Pharma Collaborations; Concluding Remarks; References; Notes; 6: A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges; Evolution of Collaborative Drug Discovery; Challenges for Collaborative Drug Discovery; Conclusion; References; Part II: Governmental Initiatives Accelerate Precompetitive Collaboration; 7: The Value of University-Industry Partnerships; Guiding Principles for University-Industry Collaborations; The Johnson Continuum; Role of Cocreation: Companies, Government, and Universities
505	8		_aFunding for Collaborations with AcademiaNew Initiatives to Transform University-Industry Collaborations; Issues Affecting University-Industry Collaborations; Differences between Large- and Small-/Medium-Sized Companies; Large Companies Share Certain Characteristics; Small- and Medium-Sized Enterprises (SMEs) Offer a Contrasting Perspective; The National Academies' University-Industry Demonstration Partnership; Strategies for Building High-Value, High Return U-I Partnerships; Conclusion; Note on this Chapter; Note; References
588			_aDescription based on print version record and CIP data provided by publisher.
650		2	_aDrug Discovery.
650		2	_aPublic-Private Sector Partnerships.
650		7	_aMEDICAL _xPharmacology. _2bisacsh
650		7	_aDrug development. _2fast _0(OCoLC)fst00898670
650		7	_aPublic-private sector cooperation. _2fast _0(OCoLC)fst01083445
650		0	_aDrug Discovery.
650		0	_aPublic-Private Sector Partnerships.
650		0	_aDrug development.
650		0	_aPublic-private sector cooperation.
650		4	_aPublic-Private Sector Partnerships.
655		4	_aElectronic books.
655		0	_aElectronic books.
700	1		_aChaguturu, Rathnam, _eeditor of compilation.
776	0	8	_iPrint version: _tCollaborative innovation in drug discovery _dHoboken, New Jersey : John Wiley & Sons Inc., [2014] _z9780470917374 _w(DLC) 2013035525
830		0	_aWiley series on technologies for the pharmaceutical industry.
856	4	0	_uhttp://onlinelibrary.wiley.com/book/10.1002/9781118778166 _zWiley Online Library
942			_2ddc _cBK
999			_c206974 _d206974